biosimilar medicines

CLINICAL EXPERIENCE WITH BIOSIMILAR ERYTHROPOIETIN*



KEY:

- BIOLOGICS INCLUDING BIOSIMILAR MEDICINES
- BIOSIMILAR MEDICINES

Source: 1 and 2

BIOSIMILAR MEDICINES: INCREASED OPTIONS FOR PHYSICIANS

MORE CHOICE OF MODERN TREATMENTS

MAJOR THERAPY AREAS

- **RHEUMATOLOGY**
  - ANKYLOSING SPONDYLITIS
  - RHEUMATOID ARTHRITIS
- **DERMATOLOGY**
  - PSORIATIC ARTHRITIS
  - PSORIASIS
- **GASTRO-INSTESTINAL**
  - ULCERATIVE COLITIS
  - CROHN'S DISEASE
- **ONCOLOGY**
  - NON-HODGKIN LYMPHOMA
  - CHRONIC LYMPHOCYTIC LEUKAEMIA
  - BREAST CANCER
- **ENDOCRINOLOGY**
  - DIABETES
  - INFERTILITY
  - PITUITARY DWARFISM
  - TURNER SYNDROME
  - PRADER-WILLI SYNDROME

Source: 1

CASE STUDY

BULGARIA
CZECH REPUBLIC
ROMANIA

1. LAUNCH OF BIOSIMILAR ERYTHROPOIETIN
2. AVERAGE INCREASE ON MEDICAL USE OF ERYTHROPOIETIN



3. MORE PATIENTS TREATED

INCREASED PATIENT ACCESS

Source: 3

SOURCE 1: Adapted from European Medicines Agency website (*www.ema.europa.eu/ema*). **SOURCE 2:** Biopharmaceutical benchmarks 2014. G. Walsh, volumen 32, number 10, October 2014. Nature Biotechnology
SOURCE 3: Adapted from IMS report: Delivering on the potential of biosimilar medicines. the role of functioning competitive markets. IMS Institute For Healthcare Informatics. march 2016.
www.imshealth.com/files/web/imsh institute/healthcare briefs/documents/ims_institute_biosimilar_brief_march_2016.pdf
For more information please see consensus information paper Q&A physicians ec.europa.eu/docsroom/documents/8242

* ERYTHROPOIETIN IS INDICATED IN THE FOLLOWING THERAPEUTIC AREAS: ANEMIA; CONSEQUENCE OF CHRONIC KIDNEY FAILURE; FOLLOW-UP OF CANCER TREATMENT (ADAPTED FROM RESPECTIVE EPAR)

Sep. 2016